Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C

Lindsay Mollison, L. Totten, J. Flexman, M. Beaman, R. Batey

    Research output: Contribution to journalArticlepeer-review

    10 Citations (Scopus)


    Background and Aim: Hepatitis C virus (HCV) is a common infection with serious health consequences. Alternative therapies are often used for hepatitis C. The aim of the present study was to examine CH100, a Chinese herbal remedy, for efficacy in therapy of chronic HCV.Methods: A randomized double blind placebo-controlled study in a tertiary outpatient clinic of CH100 over 24 weeks with 24 weeks follow-up in patients with chronic HCV infection. Alanine aminotransferase (ALT), HCV-RNA, quality of life (by SF-36) and side-effects were examined regularly. Ninety-seven patients were enrolled of which 91 were suitable for analysis.Results: No significant differences were observed between patients receiving CH100 (n = 61) or placebo (n = 30) at baseline or during follow-up in either ALT or viral titer. However, patients receiving CH100 had a fall in mean ALT over time (P = 0.05 at week 4, P = 0.26 at week 12, and P = 0.04 at week 24), with reversion to baseline during post-treatment follow up. No significant side-effects were observed although mild complaints were common. Quality of life scores improved in both groups with time, and bodily pain significantly improved in CH100 recipients.Conclusion: CH100 appears to be no better than placebo in the treatment of patients with chronic HCV infection.
    Original languageEnglish
    Pages (from-to)1184-1188
    Publication statusPublished - 2006


    Dive into the research topics of 'Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C'. Together they form a unique fingerprint.

    Cite this